Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Amortization of Deferred Charges (2016 - 2021)

Historic Amortization of Deferred Charges for Corcept Therapeutics (CORT) over the last 5 years, with Q4 2021 value amounting to $508000.0.

  • Corcept Therapeutics' Amortization of Deferred Charges rose 495.87% to $508000.0 in Q4 2021 from the same period last year, while for Dec 2021 it was $2.0 million, marking a year-over-year increase of 1653.04%. This contributed to the annual value of $2.0 million for FY2021, which is 1653.04% up from last year.
  • Corcept Therapeutics' Amortization of Deferred Charges amounted to $508000.0 in Q4 2021, which was up 495.87% from $502000.0 recorded in Q3 2021.
  • Over the past 5 years, Corcept Therapeutics' Amortization of Deferred Charges peaked at $508000.0 during Q4 2021, and registered a low of $3000.0 during Q3 2017.
  • For the 4-year period, Corcept Therapeutics' Amortization of Deferred Charges averaged around $345933.3, with its median value being $385000.0 (2020).
  • As far as peak fluctuations go, Corcept Therapeutics' Amortization of Deferred Charges crashed by 4000.0% in 2017, and later surged by 4578.31% in 2020.
  • Quarter analysis of 4 years shows Corcept Therapeutics' Amortization of Deferred Charges stood at $3000.0 in 2017, then skyrocketed by 10966.67% to $332000.0 in 2019, then soared by 45.78% to $484000.0 in 2020, then grew by 4.96% to $508000.0 in 2021.
  • Its Amortization of Deferred Charges stands at $508000.0 for Q4 2021, versus $502000.0 for Q3 2021 and $496000.0 for Q2 2021.